Several new substances are gaining focus within the therapeutic field. Retatrutide, a double GLP-1 and GIP agonist, is showing potential for metabolic management. BPC-157, or Body Protecting Fragment 157, is thought to facilitate wound healing, with multiple reports on its results. GHK-Cu, a copp